Recurrence and Survival Effect in Breast Conserving Surgery: What are the Predictive and/or Prognostic Factors?

ME Akbari--- Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran,
M Mozaffar--- Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran,
A Heidari--- Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran,
H Zirakzadeh--- Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran,
A Akbari--- Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran,
M Akbari--- Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran,
F Hosseinzadegan Shirazi--- Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Abstract


307

Background: Breast conserving surgery (BCS) is a widely accepted form of operation in patients with early breast cancer. Recurrence remains one of the greatest concerns in breast conserving surgery. It can provoke serious anxiety in the patient and, when treated by mastectomy, negate the objective of conservation.

Methods: In this study we investigated the prognostic value of demographic, clinical and pathological factors and biological markers in breast cancer patients treated with BCS. This study was performed on 258 patients who underwent BCS from 2002 to 2010. All of the surgeries were performed by a single surgical team. Recurrence and its risk factors were evaluated.

Results: The mean age of the patients at the time of diagnosis was 50. The overall 10 year survival was 81%, 5 year survival was 88% and recurrence rate after surgery was 9%. Lymphovascular Invasion (LVI) was observed in 41 (16%) patients and in 11 (48%) patients with recurrence.

Conclusion: Our study confirmed that tumors with estrogen receptor negative and LVI had more recurrence rate but other demographic, clinical and pathological factors and biological markers (progesterone receptor, P53, HER-2) did not have any significant effect on recurrence. We recommend considering LVI and estrogen receptor assay as a prognostic factor in the patients treated with BCS.

 

Key words: Breast cancer; Breast conserving surgery; Recurrence; Survival; Biological markers

Please cite this article as: Akbari ME, Mozaffar M, Heidari A, Zirakzadeh H, Akbari A, Akbari M, Hosseinizadegan Shirazi F. Recurrence and Survival Effect in Breast Conserving Surgery: What are the Predictive and/or Prognostic Factors ? Iran J Cancer Prev.2011; Vol4, No2, P49-54.

References

1. Akbari M, Cancer in Iran. 2009. Dar-al-fekr publication. ISBN: 3-55-2611-964-978.

2. Akbari ME, Khayamzadeh M, Khoshnevis SJ, Nafisi N, Akbari A. Five and ten years survival in breast cancer patient's mastectomies vs. breast conserving surgeries personal experience. Iran J Cancer Prev. 2008; 1(2):53-6.

3. Cianfrocca M, Goldstein LJ. Prognostic and predictive factors in early-stage breast cancer. Oncologist 2004; 9(6):606-16.

4. Thor AD, Moore DH II, Edgerton SM, Kawasaki ES, Reihsaus E, Lynch HT, et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 1992; 84: 845-55.

5. Noguchi S, Koyama H, Kasugai T, Tsukuma H, Tsuji N, Tsuda H, et al. A case-control study on risk factors for local recurrences of distant metastases in breast cancer patients treated with breast-conserving surgery. Oncology 1997; 54: 468-74.

6. Zhang GJ, Tsuda H, Adachi I, Fukutomi T, Yamamoto H, Hirohashi S. Prognostic indicators for breast cancer patients with one to three regional lymph node metastases, with special reference to alterations in expression levels of bcl-2, p53 and c-erbB-2 proteins. Jpn J Clin Oncol 1997; 27: 371-7.

7. Saeidi Saedi H, Seilanian Toosi M, Mirsadraei M, Roodbari S. Evaluation of Prognostic Factors In Patients with Metastatic Breast Cancer. Iran J Cancer Prev; 2008; 1(3):123-6.

8. Heydari ST, Mehrabani D, Tabei SZ, Azarpira N, Vakili MA. Survival of Breast Cancer in Southern Iran. Iran J Cancer Prev; 2009; 2(1):51-4.

9. Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002 Oct 17; 347(16):1227-32.

10. Francis M, Cakir B, Ung O, Gebski V, Boyages J. Prognosis after breast recurrence following conservative surgery and radiotherapy in patients with node-negative breast cancer. Br J Surg. 1999 Dec; 86(12):1556-62.

11. Kemperman H, Borger J, Hart A, Peterse H, Bartelink H, van Dongen J. Prognostic factors for survival after breast conserving therapy for stage I and II breast cancer: The role of local recurrence. Eur J Cancer. 1995; 31A (5):690-8.

12. Haffty BG, Brown F, Carter D, Flynn S. Evaluation of HER-2 neu oncoprotein expression as a prognostic indicator of local recurrence in conservatively treated breast cancer: a case control study. Int J Radiat Oncol Biol Phys. 1996 Jul 1; 35(4):751-7.

13. Sartor CI. Biological modifiers as potential radiosensitizers: targeting the epidermal growth factor receptor family. Semin Oncol. 2000 Dec; 27(6 Suppl 11):15-20; discussion 92-100.

14. Buchholz TA, Huang EH, Berry D, Pusztai L, Strom EA, McNeese MD, et al. Her2/neupositive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy. Int J Radiat Oncol Biol Phys. 2004 Aug 1; 59(5):1337-42.

15. López-Guerrero JA, Llombart-Cussac A, Noguera R, Navarro S, Pellin A, Almenar S, et al. HER2 amplification in recurrent breast cancer following breast-conserving therapy correlates with distant metastasis and poor survival. Int J Cancer. 2006 Apr 1; 118(7):1743-9.

16. Fisher B, Redmond C, Fisher ER, Caplan R. Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. J Clin Oncol. 1988 Jul; 6(7):1076-87.

17. Hilsenbeck SG, Ravdin PM, De Moor CA, Chamness GC, Osborne CK, Clark GM. Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat 1998; 52(1-3):227-37.

18. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998 Sep 16; 90(18):1371-88.

19. Boutrus R, Abi-Raad R, Niemierko A, Brachtel EF, Rizk L, Kelada A, et al. Does LVI predict regional nodal failure in breast cancer patients with zero to three positive lymph nodes treated with conserving surgery and radiotherapy? Implications for regional radiation. Int J Radiat Oncol Biol Phys. 2010 Nov 1; 78(3):793-8.

20. Ragage F Debled M, MacGrogan G, Brouste V, Desrousseaux M, Soubeyran I, et al. Is it useful to detect lymphovascular invasion in lymph node-positive patients with primary operable breast cancer? Cancer. 2010 Jul 1; 116(13):3093-101.

21. Schoppmann SF, Bayer G, Aumayr K, Taucher S, Geleff S, Rudas M, et al. Austrian Breast and Colorectal Cancer Study Group. Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer. Ann Surg. 2004 Aug; 240(2):306-12.

22. Truong PT, Yong CM, Abnousi F, Lee J, Kader HA, Hayashi A, et al. Lymphovascular invasion is associated with reduced locoregional control and survival in women with node-negative breast cancer treated with mastectomy and systemic therapy. J Am Coll Surg. 2005 Jun; 2006:912-21.


Full Text:

PDF

221